ZeroStack (ZSTK) Stock Price, Financials & Analysis

Key Stats

Market Cap26.79 Mn

P/E-0.15

FCF (Yr)-8.80 Mn

ROA (Yr)-153.05

EV to EBIT-0.01

Net Income (Yr)-119.73 Mn

Enterprise Value3.48 Mn

Add ratio to table…

About

ZeroStack Corp. is an asset management and pharmaceutical distribution company that integrates artificial intelligence, digital assets, and global wholesale operations. The company operates at the intersection of decentralized AI infrastructure and traditional pharmaceutical markets, positioning itself as a hybrid player in emerging and established industries. ZeroStack’s strategy centers on accumulating and managing digital assets, particularly 0G Tokens, while…

The company generates revenue primarily through its pharmaceutical distribution segment, which supplies a range of prescription medications, including cancer therapies, ADHD treatments, multiple sclerosis drugs, and antidepressants. In its digital assets segment, ZeroStack does not yet derive direct revenue but aims to create long-term value through strategic holdings, staking activities, and AI-driven asset management. The company’s treasury strategy involves accumulating cryptocurrencies, such as 0G and Bitcoin, with plans to leverage these assets for future income generation or capital appreciation.

The company operates through the following segments:

Digital Assets and AI: This segment focuses on building and managing a treasury of digital assets, with a long-term strategy centered on accumulating 0G Tokens. ZeroStack intends to hold these assets for capital appreciation and explore revenue-accretive opportunities, such as staking and AI-driven asset management. The segment also monitors regulatory developments to ensure compliance while pursuing growth in decentralized AI infrastructure.
Commercial and Wholesale: This segment encompasses the distribution of pharmaceutical products, primarily through Phatebo GmbH, which operates in Germany. Phatebo imports and exports a wide range of medications, serving healthcare providers, pharmacies, and patients across Europe. The segment leverages Germany’s position as a leading pharmaceutical market to drive revenue and expand its product offerings.

ZeroStack Corp. occupies a unique position in both the digital assets and pharmaceutical industries. In the digital assets space, the company competes with larger treasury management firms, blockchain protocols, and AI-focused asset managers. Its competitive advantage lies in its early adoption of 0G Tokens and its focus on decentralized AI infrastructure, which aligns with growing demand for scalable, verifiable AI solutions. In the pharmaceutical distribution market, ZeroStack benefits from Phatebo’s established operations in Germany, a key hub for pharmaceutical sales in Europe. The company’s hybrid model allows it to diversify risk while capitalizing on high-growth opportunities in AI and blockchain.

The company’s customer base is divided between its two core segments. In pharmaceutical distribution, ZeroStack serves hospitals, pharmacies, and healthcare providers across Europe, with a strong presence in Germany. The digital assets segment does not yet have a direct customer base but targets institutional and retail investors interested in decentralized AI and blockchain technologies. Specific customer names are not disclosed in the filing.

How ZeroStack ranks

Ranked against the 27 companies in Healthcare Payers and Distributors58 metrics · as of Nov 6, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last

P/ENegative earnings −0.15xMedian 25.1x 4^th
P/FCFNegative free cash flow −4.59xMedian 16.4x 16^th
P/Operating cash flowNegative operating cash flow −4.62xMedian 13.6x 13^th
P/S 0.65xMedian 0.40x 36^th
P/B 1.87xMedian 2.64x 74^th
P/Tangible book 1.87xMedian 3.26x 83^rd
EV/EBITDANegative EBITDA −0.11xMedian 14.2x 1^st
EV/EBITNegative EBIT −0.11xMedian 18.9x 1^st
EV/Revenue 0.64xMedian 0.44x 38^th
EV/FCFNegative free cash flow −4.55xMedian 17.8x 13^th
EV/Operating cash flowNegative operating cash flow −4.58xMedian 15.3x 13^th
PEG (3Y EPS CAGR)Negative earnings 0.00Median 1.51 Not meaningful —

Growth

14 metrics · Year-on-year growth and three-year compound annual growth

Revenue growth (1Y) 27.3%Median 6.4% 83^rd
Revenue CAGR (3Y) −13.1%Median 9.4% 9^th
Gross profit growth (1Y) 172%Median 15.2% 95^th
Gross profit CAGR (3Y) −32.4%Median 7.6% 1^st
Operating income growth (1Y) −2,574%Median 13.6% 1^st
Operating income CAGR (3Y) −57.0%Median 4.5% 4^th
Net income growth (1Y) −1,263%Median 15.4% 1^st
Net income CAGR (3Y) −37.3%Median 7.8% 4^th
EPS growth (1Y) 24.9%Median 24.2% 54^th
EPS CAGR (3Y) 64.4%Median 12.2% 91^st
Operating cash flow growth (1Y) 37.6%Median 25.0% 67^th
Operating cash flow CAGR (3Y) 23.9%Median 14.6% 70^th
Free cash flow growth (1Y) 37.9%Median 25.9% 63^rd
Free cash flow CAGR (3Y) 25.2%Median 15.9% 70^th

Profitability

14 metrics · Margins, returns on capital and the quality of earnings

Gross margin 13.1%Median 18.6% 41^st
EBITDA margin −597%Median 1.8% 5^th
Operating margin −598%Median 1.0% 4^th
Pretax margin −436%Median 1.1% 4^th
Net margin −444%Median 0.8% 4^th
FCF margin −14.1%Median 1.9% 17^th
Operating cash flow margin −14.0%Median 2.2% 17^th
Return on equity −703%Median 10.7% 1^st
Return on assets −505%Median 2.3% 4^th
Return on invested capital −852%Median 7.8% 1^st
Return on capital employed −994%Median 8.6% 1^st
Asset turnover 1.14xMedian 1.66x 17^th
Cash conversion (OCF / net income)Net income is not positive 0.03xMedian 1.63x Not meaningful —
Stock comp / revenue 13.1%Median 0.5% 15^th

Financial Health

11 metrics · Leverage, liquidity and solvency; less debt ranks higher

Debt / assets 9.6%Median 20.8% 85^th
Debt / equity 0.17xMedian 0.71x 86^th
Net debt / EBITDAEBITDA is not positive 0.00xMedian 0.66x Not meaningful —
Debt / FCFFree cash flow is not positive −0.43xMedian 3.92x Not meaningful —
Liabilities / assets 45.1%Median 70.3% 80^th
Equity / assets 54.9%Median 29.7% 80^th
Interest coverage —Median 3.24x No data —
Current ratio 0.95xMedian 1.15x 36^th
Quick ratio 0.71xMedian 0.89x 40^th
Cash ratio 0.24xMedian 0.39x 44^th
Altman Z-score −47.3Median 3.05 4^th

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	UNH	Unitedhealth Group Inc	356.05 Bn	22.42	0.79	74.33 Bn
2	MCK	Mckesson Corp	123.13 Bn	26.20	0.29	9.21 Bn
3	CVS	CVS HEALTH Corp	109.04 Bn	9.88	0.26	60.68 Bn
4	ELV	Elevance Health, Inc.	90.56 Bn	17.62	0.45	30.76 Bn
5	CI	Cigna Group	77.41 Bn	12.92	0.27	31.14 Bn
6	COR	Cencora, Inc.	66.63 Bn	25.39	0.20	11.72 Bn
7	CAH	Cardinal Health Inc	63.51 Bn	34.93	0.25	8.82 Bn
8	ZSTK	ZeroStack Corp.	0.03 Bn	-0.15	0.67	0.00 Bn

S.No.

Ticker

Company

Market Cap

P/E

P/S

Total Debt (Qtr)

UNH

Unitedhealth Group Inc

356.05 Bn

22.42

0.79

74.33 Bn

MCK

Mckesson Corp

123.13 Bn

26.20

0.29

9.21 Bn

CVS

CVS HEALTH Corp

109.04 Bn

9.88

0.26

60.68 Bn

ELV

Elevance Health, Inc.

90.56 Bn

17.62

0.45

30.76 Bn

Cigna Group

77.41 Bn

12.92

0.27

31.14 Bn

COR

Cencora, Inc.

66.63 Bn

25.39

0.20

11.72 Bn

CAH

Cardinal Health Inc

63.51 Bn

34.93

0.25

8.82 Bn

ZSTK

ZeroStack Corp.

0.03 Bn

-0.15

0.67

0.00 Bn

ZeroStack ZSTK

About

Financial Instrument Breakdown of Revenue (2025)

How ZeroStack ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

ZeroStack ZSTK

About

Financial Instrument Breakdown of Revenue (2025)

How ZeroStack ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Create an account

Sign In

Reset Password